1 / 5

Baseline Characteristics: HPS

Baseline Characteristics: HPS. Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016. HPS: Mean SE Differences in Lipids (Simvastatin – Placebo). Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016. Risk ratio and 95% CI. 0.4. 0.6. 0.8. 1.0. 1.2.

palmer-duncan
Télécharger la présentation

Baseline Characteristics: HPS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Baseline Characteristics: HPS Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.

  2. HPS: MeanSE Differences in Lipids(Simvastatin – Placebo) Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.

  3. Risk ratio and 95% CI 0.4 0.6 0.8 1.0 1.2 1.4 HPS: Major Vascular Events by Prior Diabetes STATIN Better PLACEBO Better 27% reduction (15–38)p<0.0001 24% reduction (6–39)p=0.01 17% reduction (3–30)p=0.02 22% reduction (13–30)p<0.0001 Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016. Reprinted with permission from Elsevier Science.

  4. 0 1 2 3 4 5 6 –1(6) 13(8) 34(9) 47(10) 51(15) 58(48) Benefit/1000 (SE) HPS: Major Vascular Events by Year in Patients with Diabetes Logrank p<0.00001 Placebo Patients with Events (%) Simvastatin Years of Follow-up Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016. Reprinted with permission from Elsevier Science.

  5. 0.4 0.6 0.8 1.0 1.2 1.4 HPS: Major Vascular Events by LDL-C and Prior Diabetes Risk ratio and 95% CI STATIN Better PLACEBO Better 27% reduction (13–40)p=0.0007 Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016. Reprinted with permission from Elsevier Science.

More Related